SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
PMV Pharmaceuticals entered into an underwriting agreement on August 31, 2026 and priced a public offering of approximately $50.8 million in gross proceeds, consisting of 22,055,000 shares of common stock, 19,900,000 pre-funded warrants, and 41,955,000 common stock warrants. The company intends to use proceeds to fund late-stage clinical development and commercialization of rezatapopt.
View raw filing on EDGAR →Global Mofy AI Limited entered into securities purchase agreements on August 31, 2026, for a registered direct offering of 3,796,000 Class A ordinary shares at $0.538 per share, raising approximately $2.04 million in gross proceeds. The offering was self-underwritten and registered under Form F-3. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →The filing discloses an unregistered sale of 197,461.9 shares of common stock at $9.85 per share for $1.945 million, conducted pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D. This is a classic private placement of equity securities that dilutes existing shareholders and raises capital for the company.
View raw filing on EDGAR →The filing discloses an unregistered private offering of common stock under Rule 506(c) of Regulation D, with approximately 128,166 shares issued for an aggregate purchase price of approximately $3,146,198 during August 2026. This is a classic dilutive equity issuance exempt from registration, which is material to investors as it increases share count and affects ownership dilution and per-share metrics.
View raw filing on EDGAR →The filing discloses multiple unregistered issuances of common stock by VolitionRx to Lind Global Asset Management in satisfaction of conversion obligations under senior secured convertible promissory notes. Across seven separate transactions in late August 2026, the Company issued approximately 4.4 million shares (712,328 + 520,547 + 698,630 + 695,890 + 693,151 + 690,411 + 687,671 shares) representing roughly $1.465 million in aggregate conversion value. These conversions are explicitly disclosed under Item 3.02 and rely on Section 3(a)(9), Section 4(a)(2), and Rule 506(d) exemptions—hallmarks of dilutive private equity issuances. The scale and frequency of these conversions, combined with the existing convertible debt structure, signal material dilution to existing shareholders.
View raw filing on EDGAR →The filing discloses entry into an Amended and Restated At-the-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, authorizing the issuance of up to $100,000,000 in common stock shares. This is a registered equity offering program that will dilute existing shareholders and is a material capital-raising activity typical of small-cap biotech companies. The ATM structure allows continuous issuance at market prices, making this a dilutive equity issuance under Item 1.01.
View raw filing on EDGAR →The filing discloses an unregistered private placement under Item 3.02, with the Company issuing 4,600 shares of Series B Convertible Preferred Stock (convertible into 6.57 million common shares), Series A Warrants to purchase 4.6 million shares, and Series B Warrants to purchase 4.6 million shares, for $4.6 million in gross proceeds. The filing explicitly notes the "dilutive effect of the conversion of the Series B Preferred Stock and the exercise of the Warrants" and indicates additional closings of $4.4 million are pending, representing a significant capital raise and equity dilution event material to investors.
View raw filing on EDGAR →The filing discloses stockholder approval and issuance of 12,131,122 shares of Common Stock resulting from cashless exercise of pre-funded warrants by Sarborg Limited investors, plus additional shares from an at-the-market offering program. This represents a material dilutive equity issuance that increased outstanding shares to 13,693,866 and affected the company's market capitalization and Nasdaq compliance status.
View raw filing on EDGAR →BayFirst Financial Corp. announced commencement of a rights offering to existing shareholders, offering up to 4,108,072 shares of common stock at $3.50 per share. The press release explicitly states the SEC issued a Notice of Effectiveness for the Form S-1 Registration on August 31, 2026, and the final prospectus was filed pursuant to Rule 424(b)(3). This is a material equity issuance that will dilute existing shareholders and is part of the company's "recapitalization," signaling capital-raising activity typical of dilutive issuances.
View raw filing on EDGAR →Valion Bio entered into a Letter Agreement on August 31, 2026, whereby 3i purchased 100 Series B Preferred Shares, 7,637 Series C Preferred Shares, and warrants to purchase 1,057,046 shares of Common Stock for $7.737 million under Section 4(a)(2) exemption.
View raw filing on EDGAR →The filing discloses an unregistered private placement of 207,848 shares of Series A Convertible Preferred Stock under Regulation D Rule 506(b), generating $2,052,000 in aggregate proceeds during August 2026. This is a classic dilutive equity issuance to accredited investors exempt from registration, with 13.3 million shares of the preferred stock now outstanding as of the filing date. The material capital raise and equity dilution would affect a reasonable investor's assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →Brookfield Private Equity Fund LP sold approximately $3,074,000 of unregistered limited partnership units (Class S and Class I) on August 1, 2026, pursuant to a continuous private offering exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →IX Acquisition Corp. entered into SAFE Agreements (Simple Agreements for Future Equity) with investors for an aggregate of $13,000,000 in private placements, convertible into approximately 1,130,435 shares of Parent Common Stock at $11.50 per share plus an additional 1,062,609 incentive shares held in escrow. This represents a dilutive equity issuance that will significantly increase share count upon conversion at the merger closing, materially affecting existing shareholders.
View raw filing on EDGAR →The Company disclosed termination of an equity distribution agreement with Jefferies LLC and entry into a new equity distribution agreement with Huntington Securities, Inc., both relating to an at-the-market (ATM) offering program under which the Company may offer and sell up to $500 million in common stock and preferred stock. This represents a material capital-raising mechanism that could result in significant dilution to existing shareholders, and the replacement of one sales agent with another signals ongoing reliance on this dilutive financing vehicle.
View raw filing on EDGAR →Cenntro Inc. entered into securities purchase agreements to issue up to 12.8 million shares of common stock at $3.773 per share for approximately $48.3 million in gross proceeds in a private placement exempt under Section 4(a)(2) and Regulation S. The issuance represents 20% or more of outstanding common stock and is conducted under Nasdaq Listing Rule 5635(d).
View raw filing on EDGAR →Sono Group agreed to issue and sell 283,500 Ordinary Shares (19.9% of outstanding shares) to private purchasers at market price pursuant to an effective Form S-3 registration statement, representing a material dilutive equity issuance typical of a registered direct offering.
View raw filing on EDGAR →Gilat announced a $100 million private placement of convertible notes to Israeli institutional investors, convertible into ordinary shares at $16.00 per share (60% premium to the August 28, 2026 closing price of $9.94). The notes are senior unsecured, bear 3.75% interest, and mature September 1, 2031. This is a material dilutive issuance of equity-linked securities raising capital for general corporate purposes and technology investments, with conversion mechanics that create shareholder dilution upon conversion or redemption.
View raw filing on EDGAR →BioLineRx entered into a securities purchase agreement on August 27, 2026, to sell 480,696 ADSs, pre-funded warrants to purchase 868,225 ADSs, and unregistered warrants to purchase 2,023,382 ADSs in a registered direct offering and concurrent private placement. The unregistered warrants component and the private placement structure are characteristic of a dilutive equity issuance. Aggregate gross proceeds are approximately $3.75 million, with the company intending to use net proceeds for R&D and working capital.
View raw filing on EDGAR →NaaS Technology entered into a Securities Purchase Agreement on August 28, 2026, to issue 24,024,022,400 Class A Ordinary Shares (7,507,507 ADSs) plus warrants to purchase an additional 22,880,022,400 Class A Ordinary Shares for US$25,000,000 in a private placement. The shares were issued without registration under the Securities Act in reliance on Regulation S and Regulation D, and bear restrictive legends. This is a classic dilutive private placement that materially increases share count and dilutes existing shareholders, particularly given the substantial number of shares issued and the related-party nature of the transaction involving the controlling shareholder Newlink.
View raw filing on EDGAR →T3 Defense Inc. issued 1,344,969 shares through multiple mechanisms including Form S-8 registration, conversion of Series B Convertible Preferred Shares, and exercise of warrants, increasing outstanding shares by 81% from 1,663,806 to 3,008,775 shares. This represents material dilution to existing shareholders.
View raw filing on EDGAR →Strategy Inc sold 4.5 million shares of Class A Common Stock under its at-the-market offering program during August 24–30, 2026, generating $602.8 million in net proceeds, with proceeds allocated to bitcoin purchases ($369.7 million), preferred stock repurchases, dividend funding, and cash reserves.
View raw filing on EDGAR →Warburg Pincus Access Fund sold unregistered limited partnership units totaling $15.4 million to third-party investors on August 3, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's investor base.
View raw filing on EDGAR →ONEOK issued $9 billion of Class A and Class B Units in ONEOK Holdings, L.L.C. to Apollo funds in an unregistered private placement under Section 4(a)(2) of the Securities Act, representing a substantial minority equity investment that funds the Brazos acquisition and debt reduction.
View raw filing on EDGAR →Jazz Pharmaceuticals' exchangeable senior notes offering includes provisions for unregistered issuance of up to 5,014,125 ordinary shares upon exchange, with an initial exchange rate of 4.0113 shares per $1,000 principal amount (later priced at 2.8150 shares per $1,000), creating material potential equity dilution.
View raw filing on EDGAR →The Fund completed unregistered sales of limited partnership units totaling approximately $10.0 million across two tranches (July 1 and August 3, 2026) to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D, diluting existing unitholders' ownership interests.
View raw filing on EDGAR →The Sponsor purchased 234,000 Ordinary Shares at $10.00 per share for $2.34 million in a private placement concurrent with the IPO, with transfer restrictions and registration rights typical of SPAC sponsor investments.
View raw filing on EDGAR →Kazia announced a registered public offering of 2,580,000 ADSs (representing 1.29 billion ordinary shares) plus Series A and Series B Warrants, with expected gross proceeds of approximately $40 million before underwriting costs and potential additional proceeds of ~$80 million if warrants are exercised. The offering is tranched and involves dilutive equity issuance to raise capital for clinical development.
View raw filing on EDGAR →Zedge announced a proposed private placement of Class B common stock and warrants to accredited investors for approximately $7.5 million, led by Vice Chairman Howard Jonas, with 90% warrant coverage at 110% exercise price, to accelerate DataSeeds growth.
View raw filing on EDGAR →The 6-K discloses an amendment to securities purchase agreements dated August 26, 2026, relating to the issuance of Class A ordinary shares to investors at a significant discount (20% of closing price). The Company previously issued 4,310,350 shares on July 8, 2026 and 6,329,115 shares on August 11, 2026, totaling over 10.6 million shares for $2 million in aggregate proceeds. This represents a dilutive private placement of unregistered equity securities, a material capital-raising event typical of small-cap issuers under financial pressure.
View raw filing on EDGAR →Tenon Medical completed a $3.0 million private placement on August 31, 2026, issuing 597,610 shares of common stock (or pre-funded warrants) and warrants to purchase 1,058,517 additional shares under Section 4(a)(2) and Regulation D exemptions. The company intends to use proceeds for debt repayment and working capital.
View raw filing on EDGAR →Zoomcar completed a warrant exchange offer, issuing approximately 317.7 million shares of common stock in exchange for 6.03 million existing warrants (approximately 63% of outstanding warrants). The shares were issued as restricted securities under Section 3(a)(9) exemption with no cash consideration, materially affecting the company's capital structure and warrant overhang.
View raw filing on EDGAR →The 6-K discloses entry into an At-The-Market (ATM) sales agreement on August 31, 2026, permitting the Company to offer and sell up to $50,000,000 of Class A ordinary shares through Craft Capital Management LLC. This is a dilutive equity issuance arrangement that would materially affect existing shareholders' ownership and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →The Company issued an unregistered convertible promissory note under Section 4(a)(2) of the Securities Act to an accredited investor, with shares of common stock issuable upon conversion, creating potential equity dilution.
View raw filing on EDGAR →GameStop is issuing approximately 55.5 million shares of Common Stock in a private placement to existing convertible noteholders in reliance on Section 4(a)(2) of the Securities Act, representing approximately 73% of the exchange consideration in the convertible notes restructuring.
View raw filing on EDGAR →The filing discloses unregistered sales of equity securities under Item 3.02, including 15,000,000 shares to 221 Cap (controlled by CEO Scott Gallagher) as a restricted stock award, 7,500,000 shares to Gallagher via conversion of $37,500 accrued compensation, and 6,000,000 shares to director W. Scott McBride via conversion of $30,000 accrued compensation. These represent substantial dilutive issuances relying on Section 4(a)(2) exemption. While Item 5.02(e) addresses compensatory arrangements, the primary material event disclosed is the equity issuance itself, which totals 28.5 million shares and would significantly dilute existing shareholders.
View raw filing on EDGAR →The 6-K discloses multiple dilutive equity issuances: (i) ordinary shares from conversion of a convertible note (January 27, 2025 agreement); (ii) ordinary shares under a securities purchase agreement (June 22, 2026); and (iii) 10,000,000 Class B ordinary shares issued to CEO Houqi Zhang via debt conversion (June 22, 2026). The aggregate outstanding shares increased to 66,350,064 as of August 31, 2026, reflecting material dilution to existing shareholders. While the filing itself is a bare 6-K with no exhibits, the explanatory note explicitly references and summarizes these previously disclosed issuances, making the current disclosure a material update on the company's capitalization structure.
View raw filing on EDGAR →FingerMotion entered into a securities purchase agreement on August 31, 2026 for a registered direct offering of 3,958,055 shares of common stock at $0.24 per share plus 12,708,611 pre-funded warrants. The pre-funded warrants are exercisable for one share each at $0.0001 per share, creating substantial dilution. The company expects net proceeds of approximately $4.0 million. This is a classic dilutive equity issuance disclosed under Item 1.01, material to investors assessing ownership and capital structure.
View raw filing on EDGAR →The filing discloses multiple unregistered equity issuances in August 2026: 602,491 shares to Horberg Enterprises via preferred stock exchange, 1,333,111 shares to Agile Capital Funding via debt-to-equity conversion, 1,000,000 shares to Streeterville Capital via note exchange, and 1,500,000 shares to Silverback Capital Corporation. These transactions, totaling approximately 4.4 million shares, represent substantial dilution and were issued pursuant to Section 4(a)(2) and Regulation D exemptions. Item 3.02 explicitly identifies these as unregistered sales of equity securities, and the debt-to-equity conversions (Agile and Streeterville) signal financial stress and refinancing activity typical of small-cap issuers in distress.
View raw filing on EDGAR →BranchOut Food completed a public offering of 820,588 shares at $3.40 per share on August 28, 2026, and subsequently exercised the over-allotment option for an additional 123,088 shares on August 31, 2026, resulting in total gross proceeds of approximately $3.2 million. This is a registered public offering of equity securities that dilutes existing shareholders and raises capital for the company, disclosed under Item 8.01 with supporting press release in Exhibit 99.1.
View raw filing on EDGAR →NextTrip entered into an at-the-market (ATM) offering agreement on August 31, 2026, to sell up to $6.5 million of common stock through Titan Partners Securities LLC. This is a classic dilutive equity issuance disclosed under Item 1.01 (Entry into a Material Definitive Agreement). ATM offerings are a standard capital-raising mechanism for smaller public companies and represent a material commitment to issue equity that would dilute existing shareholders.
View raw filing on EDGAR →Tecogen filed a Form S-3 registration statement on August 31, 2026, to facilitate the reoffer and resale of 4,507,603 shares of common stock by selling stockholders who acquired them in private placements exempt from registration. The registration enables previously unregistered shares to become liquid and available for public sale, which is materially dilutive to existing shareholders, subject to a 182-day lock-up period for the Hatsopoulos trusts holding 3,475,714 shares.
View raw filing on EDGAR →The filing discloses exercise of pre-funded warrants resulting in 1,604,095 shares of common stock outstanding as of August 28, 2026, with all previously outstanding pre-funded warrants now exercised. Pre-funded warrant exercises represent dilutive equity issuances that increase share count and dilute existing shareholders, a material capital structure event for investors assessing ownership and voting power.
View raw filing on EDGAR →The Company issued approximately 3.25 million common shares for $80.6 million in an unregistered offering pursuant to Section 4(a)(2) and Regulation D to accredited investors, resulting in dilution to existing shareholders.
View raw filing on EDGAR →The Company issued approximately 209,520 common shares for $5.2 million (~$24.64 per share) to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →Quoin entered into a Securities Purchase Agreement on August 27, 2026, for a private placement of up to $50.0 million in gross proceeds, consisting of 6,305,300 ADSs (or pre-funded warrants) and accompanying ordinary warrants to purchase 3,152,650 ADSs. The unregistered equity issuance under Section 4(a)(2) and Regulation D exemptions is structured as a PIPE-like transaction with insider participation, representing significant dilution to existing shareholders and expected to fund operations into the second half of 2029.
View raw filing on EDGAR →Rainier Acquisition Corp completed a private placement of 194,375 Private Placement Units at $10.00 per unit (totaling approximately $1.94 million) simultaneously with its IPO on August 28, 2026, with units issued as unregistered securities under Section 4(a)(2) exemption and restricted transferability until 30 days after the initial business combination.
View raw filing on EDGAR →Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an "at the market offering" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.
View raw filing on EDGAR →BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R&D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.
View raw filing on EDGAR →CVC-PE Global Private Equity Fund, LP sold approximately $37.0 million in unregistered limited partnership units on August 1, 2026, as part of a continuous private offering exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →The Company sold 83,485.841 Class I common shares for approximately $1.7 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D/S, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →